Header

Leukemia/MDS Clinical Trials

Category:Adult
Status:Active

Displaying trials 1 - 30 of 48 in total

Double Cord Versus Haploidentical (BMT CTN 1101)

Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar tissue type can b...

Diagnosis: Leukemia/MDS, Hodgkin's Lymphoma

Phase: 3

Protocol Number: 12-188

Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakp...

Diagnosis: Leukemia/MDS

Phase: 3

Protocol Number: 15-709

P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies

The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.

Diagnosis: Non-Hodgkin's Lymphoma, Leukemia/MDS

Phase: 3

Protocol Number: 14-179

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

This research is a phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether it works in treating a specific cancer. "Investi...

Diagnosis: Leukemia/MDS

Phase: 2

Protocol Number: 12-128

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

The goal of this clinical research study is to compare how 2 different drugs, decitabine and azacitidine, when given on a shorter than standard dosing schedule, may help to control MDS. The safety ...

Diagnosis: Leukemia/MDS

Phase: 2

Protocol Number: 15-180

Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies

We propose a multi-institutional phase II haplo-identical T cell replete BMT study in children with high-risk leukemias. The myeloablative conditioning regimen prescribed will be TBI-based for lymp...

Diagnosis: Leukemia/MDS

Phase: 2

Protocol Number: 16-605

Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In this research study we will start by looking for the highest dose of pyrimethamine that can be given safely to CLL patients without severe or unmanageable side effects. This dose will then be us...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 09-421

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS

This 2-stage, open-label study will evaluate safety and pharmacokinetics of ASTX727, as well as determine the dose for the study's second stage. In the second stage the selected dose will be co...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-195

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) both alone and in combination with decitabine. GO-203-2c targets ...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-222

SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

This is a non-randomized, open-label, multi center study. A cycle of therapy is 5 consecutive days every 21 days for 6 or more cycles. Stage I will consist of a brief run-in period in which patient...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-454

A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib

The purpose of this study is to find out if treating Chronic Myelomonocytic Leukemia (CMML) with a study drug [ruxolitinib] can improve outcomes of patients with CMML. The first step of the study i...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 14-384

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

This is a non-randomized open label multi-center study. Patients who are in their first complete remission (CR) following induction therapy will be treated with SL-401, which will be administered a...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 15-456

A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral A-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)

This Phase 1b/2 study is an open-label, randomized, multicenter trial to evaluate the safety and efficacy of oral AG-120 + SC azacitidine and oral A-221 + Subcutaneous (SC) azacitidine in subjects ...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 16-057

SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)

This is a non-randomized open label multi-center study. Patients with high-risk myeloproliferative neoplasms (systemic mastocytosis [SM], advanced symptomatic hypereosinoophic disorder [PED], myelo...

Diagnosis: Leukemia/MDS

Phase: 1 / 2

Protocol Number: 16-149

Brentuximab Vedotin + Chemo for AML

This research study is a Phase I clinical trial. Phase I trials test the safety of an investigational drug or combination of drugs. These trials also try to define the appropriate dose of the inves...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 13-040

A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in CML and Ph+ ALL patients who are relapsed or refractory ...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-117

Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults

This research study is evaluating a combination of drugs considered standard treatment for children and young adults with acute lymphoblastic leukemia (ALL), in combination with a new drug called M...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-200

Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

This research study is evaluating drugs called bortezomib and lenalidomide as a possible treatment for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The purpose of this research s...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-213

A Dose Escalation and Cohort Expansion Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

TEN-010 is a small molecule, bromodomain and extra-terminal domain (BET) bromodomain inhibitor. This study is designed to characterize the safety, tolerability, and pharmacokinetics of TEN-010 in p...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 14-505

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

This research study is evaluating a combination of two drugs, ibrutinib and obinutuzumab, as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 15-283

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

To determine and evaluate a safe and tolerated dose of HDM201 in adult patients with selected advanced tumors characterized by wild-type TP53.

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 15-289

MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age

This research study is evaluating drugs called Millennium 9708 (referred to as MLN9708) in combination with standard therapy for acute myeloid leukemia (AML) consisting of daunorubicin and cytarabi...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 15-276

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

This is an open label, multicenter Phase 1 study to determine the MTD, dosing schedule and RP2D of IMGN779 when administered as mono-therapy to adult AML patients with CD33 -positive disease.

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 16-215

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 16-426

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

This study will find the highest acceptable treatment dose of cord blood, culture expanded natural killer (NK) cells, a kind of immune cell, in patients with relapsed and/or refractory acute myeloi...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 16-373

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ipilimumab when given together with decitabine in treating patients with myelodysplastic syndrome or acute myeloid leukemia that has ret...

Diagnosis: Leukemia/MDS

Phase: 1

Protocol Number: 17-718

Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)

This is a Phase 1b, open-label, non-randomized, multicenter study to evaluate the safety of orally administered ABT-199 combined with decitabine or azacitidine and the preliminary efficacy of these...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 14-353

Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

This is a Phase 1, open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of BLU-285, administered...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 15-559

Study of INCB053914 in Subjects With Advanced Malignancies

This is an open-label, dose-escalation study of the PIM kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 2 parts. Part 1 (dose escalation) will eva...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 15-576

Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

This two-stage study is designed to investigate the antitumor activity of tipifarnib in approximately 58 eligible subjects with very low, low or INT risk MDS who have no known curative treatment. E...

Diagnosis: Leukemia/MDS

Phase:

Protocol Number: 16-181

1
<< Previous
'